Upvote
Downvote
Chief Scientific Officer
Share Job
- Suggest Revision
- Experience working in gene therapy, gene editing/CRISPR, and/or RNAi required
- Kelonia Therapeutics is a preclinical, biotechnology company pioneering a new wave of genetic medicines using its in vivo gene placement system (iGPS).
- By enabling precisely targeted, highly efficient, manufacturable off-the-shelf in vivo delivery, Kelonia s technology has the potential to revolutionize gene therapy and dramatically expand the impact and reach of genetic medicines to every patient in need and can be applied to a broad range of diseases.
- In addition, Kelonia recently announced a research collaboration and license agreement with Astellas Pharma to develop novel immuno-oncology therapeutics.
- With this agreement, Kelonia will receive $40 million upfront for the first program, an additional $35 million should Astellas exercise its options for a second program, potential milestones and contingency payments approaching $800 million in total, and R&D funding for work performed in the collaboration.
Active Job
Updated TodaySimilar Job
Relevance
Active